

TheraSource LLC

A Biopharmaceutical Company

Contact: Ping Wang

Location: Long Island, New York

Email: pwang@nshs.edu

Tel: 516-641-0196

Website: www.therasourcelc.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: Biopharmaceuticals

Company Overview: TheraSource LLC is an early-stage biopharmaceutical R&D company. Our mission is to discover and develop novel medicines for the treatment of sepsis, ischemia/reperfusion injury, and hemorrhage. We focus on these unmet medical needs by developing peptide-based therapeutic products such as adrenomedulin (AM) and its binding protein (AMBP-1). An additional technology platform is being developed to enhance the phagocytosis of apoptotic cells by using the opsonizing protein MFG-E8 in inflammatory diseases. TheraSource LLC is seeking to establish strategic alliances for further development of its therapeutics.

Target Market(s): Bowel ischemia-reperfusion injury, renal ischemia-reperfusion injury, shock, trauma, and hemorrhage.

Management

Leadership:

Ping Wang, MD, President and CEO

- Raised \$6 million
- Eight issued or pending patents
- 20-year research experience
- >250 peer-reviewed publications

Mian Zhou, MD, Vice President, Operations and Finance
Rongqian Wu, MD/PhD, Director of Research

Advisory Board:

TheraSource is currently establishing an advisory board with business, science, and commercialization professionals.

Key Value Drivers

Technology: Human AM/AMBP-1 in the treatment of human diseases, such as ischemia-reperfusion injury, shock, trauma, and hemorrhage.

Competitive Advantage: 1) Combination of naturally occurring compounds; 2) Cardiovascular protection and anti-inflammatory activities; 3) Low mental and physical side effects; and 4) Indications - sepsis, ischemia/reperfusion injury, hemorrhage.

Plan & Strategy: Seeking strategic partners, alliances and licensing relationships.

*Technology funded by the NIH and being commercialized under the NIH-CAP.

Product Development

Sepsis Indication:

- | | |
|---------------------------|---------------|
| • IND application to FDA | 2009-2010 |
| • Phase I clinical trials | 2010-2011 |
| • Phase IIA & IIB | 2012 & beyond |

Bowel Ischemia-Reperfusion Indication:

- | | |
|--------------------------|---------------|
| • IND application to FDA | 2010 |
| • Phase I clinical trial | 2011 |
| • Phase IIA & IIB | 2012 & beyond |